Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site

Prostate Cancer


Gouri Shankar Bhattacharyya


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


G.S. Bhattacharyya1, H. Malhotra2, K.G. Babu3, A. Ranade4, A. Vora5, G. Biswas6, S. Basu7

Author affiliations

  • 1 Medical Oncology, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, 700064 - Kolkata/IN
  • 2 Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Hospital,, 302022 - Jaipur/IN
  • 3 Medical Oncology, HCG Hospitals, Bangalore, 560027 - Bengaluru/IN
  • 4 Medical Oncology, Jupiter Hospital, 411045 - Pune/IN
  • 5 Medical Oncology, W Pratiksha Hospital, 122002 - Gurugram, Haryana/IN
  • 6 Medical Oncology, Sparsh Hospital, 7510007 - Bhubaneswar/IN
  • 7 Urology, Fortis Hospital, 700107 - Kolkata/IN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4913


Patients with carcinoma prostate undergo rapid decline in bone health as measured by bone mineral density in the first 6 to 12 months of treatment with androgen deprivation. The WHO has developed the FRAX (Fracture Risk Assessment) Tool to predict long-term risk of major fractures and hip fracture. Guidelines are available for managing therapy related osteoporosis. This study is to characterize the risk (based on the FRAX tool) and management on the basis of guidelines in view of non-availability of bone matrix density assessments on basis of DEXA Scan.


A retrospective analysis of 196 consecutive patients receiving LHRH agonists at a single practice for the period of 2010 to 2018 was done. Data was collected after IRB clearance and included demographics, medical history, treatment history, history of ADT, bone health and its management. 10y fracture risk was calculated using the FRAX tool. Descriptive statistics were used for demographic analysis and to characterise the management of bone health. Paired t-Test was used to compare 10y fracture pre and post ADT.


A total of 196 patients were seen. The mean age was 65.5y. 36% patients had Stage II disease and 56% had Stage III disease. All patients had PSA >10 and a Gleason Score >7 and Life expectancy <10y. 97% patients received LHRH agonists for a mean period of 13.8 + 18.1 months. 57% patients had >2 Risk for osteoporosis. Counselling for adverse effect of ADT and bone side effects was seen in 20% of patients. Bone health assessment was not available for 75% of patients. Bisphosphonate therapy was seen in 3% of patients. The risk of sustaining a major fracture increased from 26% to 34% (P < 0.001) on initiation of ADT. The risk of sustaining a hip fracture rose from 12% to 20%. Guidelines was followed for DEXA Scan, Calcium supplements and Vitamin D in 22%, 15%, and 8% respectively.


In addition to predisposing factors of osteoporosis, ADT increases risk of fracture in patients with ca prostate. There is room for improvement by increasing health literacy in multi-disciplinary team and Care providers. This is the first paper of its kind in developing countries including quality practice audit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

G S Bhattacharyya.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.